749 results on '"Molin, Daniel"'
Search Results
2. Improved automated tumor segmentation in whole-body 3D scans using multi-directional 2D projection-based priors
3. Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
4. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
5. Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival – a Swedish Lymphoma Register Study
6. Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls
7. An image registration method for voxel-wise analysis of whole-body oncological PET-CT
8. Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial
9. Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival - a Swedish Lymphoma Register Study
10. Aging Kairos: treating older Hodgkin patients
11. Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma
12. Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma
13. Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial
14. Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma
15. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
16. NLPHL: a hummingbird in an owl’s nest
17. P179 / #133 - ANALYTICAL MODELLING OF NEUTRONS PRODUCED IN MEDIASTINAL CLASSICAL HODGKIN LYMPHOMA PROTON THERAPY TREATMENTS.
18. SO010 / #602 - THE INFLUENCE OF RBE ON SECOND CANCER ESTIMATES IN PROTON THERAPY
19. 2128: Individual organ dose calculations from CT imaging of Hodgkin lymphoma patients treated with protons
20. 1265: Comparison of total out-of-field dose in 6 MV VMAT and proton therapy for classical Hodgkin lymphoma
21. Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
22. Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway—A population‐based matched cohort study
23. Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study
24. Direct detection of nano-scale extracellular vesicles derived from inflammation-triggered endothelial cells using surface plasmon resonance
25. In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy
26. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study
27. Electrical stimulation promotes the angiogenic potential of adipose-derived stem cells
28. Low molecular weight poly (2-dimethylamino ethylmethacrylate) polymers with controlled positioned fluorescent labeling: Synthesis, characterization and in vitro interaction with human endothelial cells
29. Blood Milieu in Acute Myocardial Infarction Reprograms Human Macrophages for Trauma Repair
30. Treatment-Related Circulatory Diseases and Mortality in Hodgkin Lymphoma Patients Using Multi-State Modelling and Relative Survival
31. Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy
32. Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
33. P045: Plasma proteome profiling of cardiotoxicity in patients with Hodgkin lymphoma
34. T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
35. P081: Treatment-related circulatory diseases and mortality in Hodgkin lymphoma patients using multi-state modelling and relative survival
36. T082: AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients
37. P091: Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin lymphoma patients
38. P096: Polymorphisms in SETD7 may predispose the risk of developing late cardiac side effects after radiotherapy including the mediastinum in Hodgkin’ s lymphoma.
39. Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue
40. An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome
41. Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy
42. Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls
43. Checkpoint CD47 expression in classical Hodgkin lymphoma
44. Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases-A Possible Association with High Rheumatoid Arthritis Disease Activity
45. Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
46. Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy
47. Blood Milieu in Acute Myocardial Infarction Reprograms Human Macrophages for Trauma Repair.
48. CXCL1 promotes arteriogenesis through enhanced monocyte recruitment into the peri-collateral space
49. Checkpoint CD47 expression in classical Hodgkin lymphoma
50. Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases—A Possible Association with High Rheumatoid Arthritis Disease Activity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.